GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (ASX:GTG) » Definitions » Cyclically Adjusted PB Ratio

Genetic Technologies (ASX:GTG) Cyclically Adjusted PB Ratio : 0.04 (As of Jul. 06, 2025)


View and export this data going back to 1987. Start your Free Trial

What is Genetic Technologies Cyclically Adjusted PB Ratio?

As of today (2025-07-06), Genetic Technologies's current share price is A$0.039. Genetic Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was A$1.06. Genetic Technologies's Cyclically Adjusted PB Ratio for today is 0.04.

The historical rank and industry rank for Genetic Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

ASX:GTG's Cyclically Adjusted PB Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.94
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genetic Technologies's adjusted book value per share data for the three months ended in Jun. 2024 was A$0.014. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is A$1.06 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genetic Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genetic Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Cyclically Adjusted PB Ratio Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.34 0.14 0.16 0.07

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.10 - 0.07 -

Competitive Comparison of Genetic Technologies's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Genetic Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Cyclically Adjusted PB Ratio falls into.


;
;

Genetic Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genetic Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.039/1.06
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Genetic Technologies's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.014/128.9064*128.9064
=0.014

Current CPI (Jun. 2024) = 128.9064.

Genetic Technologies Quarterly Data

Book Value per Share CPI Adj_Book
200912 2.241 87.578 3.299
201006 1.276 88.971 1.849
201012 2.275 89.993 3.259
201106 1.525 92.129 2.134
201112 2.882 92.686 4.008
201203 0.000 92.779 0.000
201206 2.861 93.244 3.955
201212 2.121 94.730 2.886
201303 0.000 95.101 0.000
201306 1.107 95.473 1.495
201312 1.168 97.330 1.547
201406 0.278 98.352 0.364
201412 0.033 99.002 0.043
201506 1.032 99.838 1.332
201512 0.869 100.673 1.113
201606 0.647 100.859 0.827
201612 0.564 102.159 0.712
201706 0.405 102.809 0.508
201712 0.281 104.110 0.348
201806 0.181 104.945 0.222
201812 0.107 105.967 0.130
201906 0.056 106.617 0.068
201912 0.070 107.917 0.084
202006 0.186 106.246 0.226
202009 0.000 107.917 0.000
202012 0.212 108.846 0.251
202103 0.000 109.496 0.000
202106 0.239 110.332 0.279
202109 0.000 111.168 0.000
202112 0.211 112.654 0.241
202203 0.000 115.069 0.000
202206 0.178 117.112 0.196
202209 0.000 119.248 0.000
202212 0.119 121.477 0.126
202303 0.000 123.148 0.000
202306 0.097 124.170 0.101
202309 0.000 125.656 0.000
202312 0.042 126.399 0.043
202403 0.000 127.606 0.000
202406 0.014 128.906 0.014

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genetic Technologies  (ASX:GTG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genetic Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies Business Description

Traded in Other Exchanges
N/A
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies Headlines

No Headlines